Core Insights - Analysts project Organon (OGN) will report quarterly earnings of $0.94 per share, a decline of 16.1% year over year, with revenues expected to reach $1.55 billion, down 3.4% from the same quarter last year [1] Revenue Projections - Revenue from Women's Health for Nexplanon/Implanon NXT is estimated at $258.98 million, reflecting a year-over-year increase of +7% [4] - Revenue from Women's Health for Follistim AQ is projected to be $69.57 million, indicating a year-over-year increase of +12.2% [4] - Total revenue from Established Brands is expected to be $905.64 million, showing a decline of -6% from the prior-year quarter [4] - Revenue from Biosimilars Total is anticipated to be $153.98 million, representing a decrease of -6.1% from the year-ago quarter [5] - Revenue from Women's Health in the U.S. for Nexplanon/Implanon NXT is estimated at $183.28 million, indicating a year-over-year increase of +7.2% [5] - Geographic Revenue from the U.S. is projected to be $437.92 million, reflecting a year-over-year increase of +12.9% [5] - Revenue from Women's Health in the U.S. for NuvaRing is expected to be $7.00 million, suggesting a decline of -30% year over year [6] - Revenue from Women's Health in the U.S. for Follistim AQ is projected to reach $28.03 million, indicating a year-over-year increase of +27.4% [6] - Revenue from Established Brands in the U.S. for Respiratory- Other is expected to be $8.30 million, reflecting a year-over-year increase of +3.8% [7] - Geographic Revenue from Other International is projected to be $21.74 million, indicating a decline of -37.9% year over year [7] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Other is expected to reach $72.24 million, suggesting a decline of -1% year over year [7] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Diprospan is projected to be $37.63 million, reflecting a year-over-year increase of +1.7% [8] Stock Performance - Over the past month, Organon shares have returned -2.6%, contrasting with the Zacks S&P 500 composite's +2.3% change [8] - Organon currently holds a Zacks Rank 2 (Buy), indicating potential outperformance against the overall market in the near future [8]

Core Insights - Analysts expect Organon (OGN) to report quarterly earnings of $0.92 per share, reflecting a year-over-year decline of 24.6% and revenues of $1.54 billion, down 4.9% from the previous year [1] - There has been a downward revision of 1.7% in the consensus EPS estimate over the last 30 days, indicating a reconsideration of initial forecasts by analysts [1][2] Revenue Estimates - Revenue from Women's Health for Nexplanon/Implanon NXT is projected at $236.63 million, showing a year-over-year increase of 7.6% [4] - The consensus estimate for Biosimilars Total revenue is $153.47 million, indicating a decline of 9.7% from the year-ago quarter [4] - Revenue for Women's Health from NuvaRing is estimated at $25.26 million, reflecting a significant decrease of 33.5% year-over-year [4] - Revenue from Women's Health for Follistim AQ is expected to be $55.48 million, marking a year-over-year increase of 20.6% [5] - U.S. revenue for Nexplanon/Implanon NXT is projected at $165.06 million, indicating a growth of 7.9% from the previous year [5] - Geographic Revenue from the U.S. is expected to reach $407.08 million, suggesting a year-over-year increase of 9.7% [6] - Revenue from Women's Health for U.S. NuvaRing is forecasted at $8.12 million, indicating a substantial decline of 49.2% from the year-ago quarter [6] - Revenue from Women's Health for U.S. Follistim AQ is estimated at $18.97 million, reflecting a significant increase of 72.4% year-over-year [6] - Revenue from Established Brands in the U.S. for Respiratory- Other is projected at $7.68 million, indicating a year-over-year increase of 9.8% [7] - Geographic Revenue from Other International is expected to be $25.18 million, reflecting a decline of 13.2% from the prior-year quarter [7] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Other is estimated at $68.21 million, suggesting a slight increase of 0.3% year-over-year [8] - Revenue from Established Brands International for Non-Opioid Pain, Bone and Dermatology- Diprospan is projected at $30.94 million, indicating a year-over-year increase of 6.7% [8] Stock Performance - Over the past month, Organon shares have declined by 15.9%, compared to a 4.3% decline in the Zacks S&P 500 composite [8]